Pembelian
Synthetic Biologics Bullish Momentum
Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol.
A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients receiving SYN-004 also demonstrated significantly better maintenance and recovery of the gut microbiome as well as lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE. (Source: prnewswire.com)
Please leave me a message if you want to test the buy and sell indicators that i am using.
A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients receiving SYN-004 also demonstrated significantly better maintenance and recovery of the gut microbiome as well as lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE. (Source: prnewswire.com)
Please leave me a message if you want to test the buy and sell indicators that i am using.
Copy my trades: partner.bybit.com/b/best_copy_trading
BUY-SELL INDICATORS: bit.ly/indicatorz
TRADING COURSE: bit.ly/10Xtrading
STOCK OPTIONS SIGNALS: bit.ly/options_signals
BUY-SELL INDICATORS: bit.ly/indicatorz
TRADING COURSE: bit.ly/10Xtrading
STOCK OPTIONS SIGNALS: bit.ly/options_signals
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.